519 672 2121
Close mobile menu
Published on: 10 Jan 2024 By

Large foodborne illness outbreak linked to Cantaloupe contaminated with Salmonella

As of December 22, 2023, there have been seven deaths and 164 confirmed cases of Salmonella in Canada linked to a nationwide outbreak arising from contaminated Cantaloupes. Symptoms of Salmonella infection include: Symptoms typically develop within 6 to 72 hours after consuming contaminated …

View the post titled Large foodborne illness outbreak linked to Cantaloupe contaminated with Salmonella
Published on: 28 Dec 2023 By

McLean v. Canada (Attorney General) highlights the importance of filing a timely claim for compensation in a class action

A recent Federal Court case highlights the importance of timely claims in a class action claims process. While late claims may be accepted in extenuating circumstances, courts generally do not have jurisdiction to modify a settlement entered into by the parties. In McLean v. Canada (Attorney…

View the post titled McLean v. Canada (Attorney General) highlights the importance of filing a timely claim for compensation in a class action
Published on: 22 Dec 2023 By

FAQ: I am affected by a class action. How does compensation work?

When a class member learns that they are part of a class action, they often wonder what that means in terms of compensation. Class actions often deal with complex issues, and it can take many years for the action to be resolved. When the action is resolved by way of settlement or monetary ju…

View the post titled FAQ: I am affected by a class action. How does compensation work?
Published on: 5 Dec 2023 By

Banman v Ontario, the preferable procedure requirement, and institutional abuse litigation

The first stage of a class proceeding is the certification stage. Certification is a procedural step, the purpose of which is to screen out cases that are not appropriate to be dealt with on a class-wide basis. In Ontario, an action is certified if it passes the five-step test outlined in se…

View the post titled Banman v Ontario, the preferable procedure requirement, and institutional abuse litigation
Published on: 1 Nov 2023 By ,

Class Action pursued for Canadians alleging harms from Ozempic, semaglutide drugs

Ozempic, the popular drug approved in Canada to treat diabetes, has been linked to serious harms to users. Studies have shown a link between the use of semaglutide – the active ingredient in Ozempic – and an increased risk of severe gallbladder-related harms, including gallstones, and gastro…

View the post titled Class Action pursued for Canadians alleging harms from Ozempic, semaglutide drugs
Published on: 20 Oct 2023 By ,

Bard PowerPort Catheters: Device failures linked to health risks

Implantable catheter products, sometimes called “ports,” are medical devices used to provide long-term access to major veins in the body. The device is implanted in the body and sits just under the skin, allowing repeat access for the delivery of medications, fluids, nutrition, or blood. The…

View the post titled Bard PowerPort Catheters: Device failures linked to health risks
Published on: 23 Aug 2023 By

Ozempic for weight loss? Know the risks of off-label prescriptions

Ozempic (semaglutide) is a prescription drug approved to treat type 2 diabetes that has become one of the most in-demand medications in North America in recent years. Demand for Ozempic, which is manufactured by Novo Nordisk, has driven shortages in the United States. Health Canada observed …

View the post titled Ozempic for weight loss? Know the risks of off-label prescriptions
Published on: 9 Aug 2023 By

Bladder drug Elmiron – linked to vision loss, macular degeneration – still among top non-patented drugs in Canada per 2023 report

Elmiron, a medication prescribed for bladder issues that has been linked to a unique form of macular degeneration causing vision loss, continues to rank among the top publicly funded non-patented drugs in Canada, according to a government report on public drug plan expenditures published ear…

View the post titled Bladder drug Elmiron – linked to vision loss, macular degeneration – still among top non-patented drugs in Canada per 2023 report
Published on: 1 Aug 2023 By

Ontario Court of Appeal decides non-party litigation funders not liable for defendants’ costs in Davies v. Clarington (Municipality)

In Davies v. Clarington (Municipality), 2023 ONCA 376, the Ontario Court of Appeal reached the reasonable conclusion that non-party lenders with no involvement in directing litigation are not liable to pay an adverse costs award that a plaintiff will not pay.  On this appeal, the Court provi…

View the post titled Ontario Court of Appeal decides non-party litigation funders not liable for defendants’ costs in Davies v. Clarington (Municipality)